Major single-day swings are a common occurrence in the biotech sector, as strong late-stage clinical results can send a stock surging. That's exactly what happened on Dec. 16 when Axsome Therapeutics (NASDAQ: AXSM), a $2.8 billion clinical-stage biotech stock, rose by 70.6% over the course of the day in response to new results for its late-stage depression drug.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,